Susan Hasty, Publisher
Table of Contents . . . October 25th, 1999Non-Subscriber - Summaries Only
Interferon Therapy (HCV) - Chinese Studies Show Consensus Interferon Efficacious
Conference Coverage (ICAAC) - CpG Immunostimulation: More than Mice
Disease Progression (HBV) - Mutations May Be To Blame for Liver Cancer Risk in HBV+
Etiology (HGV/HCV Coinfection) - HGV Rare in U.S. HCV Patients with Mixed Cryoglobulinemia
Fatigue (HCV) - Fatigue in HCV + Women Studied
HBV Immunology - Core Promoter Mutation Diversity Involved in HBV Clearance
Hepatitis C Virology - HCV Quasispecies Are Distributed Nonrandomly in Plasma
Immunization (HBV) - Street Youths Should Be Focus of HBV Vaccine Efforts
Immunoreactivity (HCV) - Insufficient IL-1(beta) in HCV Sinusoidal Cells Linked to Viral Persistence
Interferon Therapy (Side Effects) - Interferon Doesn't Impact Bone Density in Rat Model
Pathogenesis (HBV) - Escape Mutations Facilitate Chronic HBV Infection
Pathogenesis (HCV) - Iron Status in HCV May Modulate Th1/Th2 Response
Transgene Expression - WHV Element Has Role in Gene Therapy
Vector Development - Liver Still Elusive Holy Grail of Gene Therapy
Drug Development (Antiviral) - "ATP-Binding Domain of Flaviviridae RNA Helicase as a Target for Antiviral Therapy."
Disease Associations (Diabetes/HCV) - "High Prevalence of Diabetes Mellitus Among Adult beta-Thalassaemic Patients with Chronic Hepatitis C."
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.